BeOne Medicines AG (ONC)
BeOne Medicines AG (ONC) is a healthcare company (biotechnology) based in Switzerland. The share price is $410.15, down 0.28% on the day, which values the company at $46.85B. Price as of 17 Nov 2026, 17:23 UTC, from Yahoo Finance.
Key facts
- Share price
- $410.15−0.28% today
- Market value
- $46.85B
- P/E ratio
- 52.6×last 12 months
- Forward P/E
- 38.3×
- Funk Score
- 71/100
- Against its own history
- Well above its usual priceusual price $273.35
- 200-week average
- $245.6567% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
BeOne Medicines AG in more detail
ONC trades at 52.6× its last twelve months' earnings, 38.3× next year's expected earnings, 7.1× sales. Measured against its own history, the price is 50% above what its usual multiples would imply ($273.35) — well above its usual price. It sits 67% above its 200-week average of $245.65.
Over the last five fiscal years BeOne Medicines AG has compounded revenue 76.8% a year. Its Funk Score is 71 out of 100 (financial strength 8.2, profitability 6.2, growth 10.0, value 4.1, each out of 10).
In its favour: Altman Z in the safe zone; Strong Piotroski score. Worth checking: Share count keeps rising.
6 of the superinvestors tracked here hold ONC, including Julian and Felix Baker (12.6% of the portfolio), Primecap team (1.1% of the portfolio), Ken Griffin (0.2% of the portfolio).
Superinvestors holding ONC
6 of the investors tracked here report a position in their latest 13F filing.
- Julian and Felix Baker Baker Bros. Advisors12.6% of portfolio · $2.5B · added · Q2 2026
- Primecap team Primecap Management1.11% of portfolio · $1.8B · trimmed · Q3 2026
- Ken Griffin Citadel Advisors0.23% of portfolio · $406.2M · added · Q2 2026
- Sarah Ketterer Causeway Capital Management0.22% of portfolio · $19.8M · new · Q3 2026
- Temasek Temasek Holdings0.21% of portfolio · $75.2M · trimmed · Q3 2026
- John Overdeck and David Siegel (founders) Two Sigma Investments0.18% of portfolio · $240.3M · added · Q3 2026
Health Care companies of similar size
- Edwards LifesciencesEW
- Becton, DickinsonBDX
- IDEXX LaboratoriesIDXX
- MedlineMDLN
- HumanaHUM
- Agilent TechnologiesA
- Teva Pharmaceutical IndustriesTEVA
- WatersWAT
- NateraNTRA
- IQVIA HoldingsIQV
- Revolution MedicinesRVMD
- Royalty PharmaRPRX
Side by side:ONC vs WAT (BeOne Medicines AG vs Waters)ONC vs NTRA (BeOne Medicines AG vs Natera)ONC vs IQV (BeOne Medicines AG vs IQVIA Holdings)ONC vs TEVA (BeOne Medicines AG vs Teva Pharmaceutical Industries)ONC vs A (BeOne Medicines AG vs Agilent Technologies)
All health care companies by market valueLargest companies in SwitzerlandAll stocks A–Z
BeOne Medicines AG (ONC): questions and answers
What is ONC's P/E ratio?
BeOne Medicines AG trades at 52.6× its last twelve months' earnings and 38.3× next year's expected earnings.
What is ONC's PEG ratio?
BeOne Medicines AG's PEG ratio is 0.73 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is BeOne Medicines AG's market cap?
BeOne Medicines AG is valued at $46.85B at a share price of $410.15.
Is ONC overvalued or undervalued?
Against its own history, ONC is well above its usual price: the price is 50% above the $273.35 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is ONC above its 200-week moving average?
Yes. ONC is 67.0% above its 200-week average of $245.65. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is BeOne Medicines AG growing?
Over the last five fiscal years BeOne Medicines AG's revenue grew 76.8% a year; over ten years revenue grew 89.8% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “BeOne Medicines AG (ONC) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ONC
Underlying data: Yahoo Finance; company filings with the SEC.